Rivastigmine Patch, Extended Release
Product Images NDC 70710-1198

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 70710-1198). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 01)

Chemical structure of rivastigmine, showing its molecular framework with labeled carbon, nitrogen, hydrogen, and oxygen atoms arranged in aromatic and aliphatic groups.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 02)

A cross-sectional illustration showing four distinct layers of a transdermal patch, labeled Layer 1 through Layer 4, indicating the structural composition of the patch.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 03)

A line graph showing rivastigmine plasma concentration (ng/mL) over 24 hours for three extended-release transdermal patch strengths: 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours. The graph plots concentration against time (hours) and displays error bars for each data point.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 04)

A line graph showing least square means change from baseline ADAS-Cog rating over 24 weeks during treatment. The graph compares clinical improvement and decline for Rivastigmine dosages of 17.4 mg/24 hours, 9.5 mg/24 hours, 6 mg capsules BID, and placebo, demonstrating trends in cognitive assessment scores over time.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 05)

Bar graph depicting the percentage of patients by ADCS-CGIC rating categories: Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. Data compares Rivastigmine patches at 17.4 mg/24 hours and 9.5 mg/24 hours, capsules 6 mg BID, and placebo groups.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 06)

A line graph illustrating the ADCI-ADL change from baseline over 48 weeks of treatment for Rivastigmine Transdermal System at 9.5 mg/24 hr and 13.3 mg/24 hr strengths. The graph compares clinical improvement and decline with data points and error bars, showing greater clinical decline at 9.5 mg/24 hr than at 13.3 mg/24 hr over time. Statistically significant differences are indicated between the two strengths.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 07)

A line graph comparing the ADAS-Cog change from baseline (LS means and SEM) over 48 weeks of treatment for Rivastigmine Transdermal System at 13.3 mg/24 hr and 9.5 mg/24 hr doses. The y-axis represents cognitive change with clinical improvement and decline indicated, and the x-axis represents weeks of treatment. Data points include error bars, with a statistically significant difference noted at week 24 favoring the 13.3 mg/24 hr dose.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 08)

Line graph depicting least squares mean change with standard errors over 24 weeks of treatment comparing Rivastigmine Transdermal System 13.3 mg/24 hr and 4.6 mg/24 hr. The y-axis shows LS mean change with clinical improvement and decline indicated, while the x-axis shows weeks of treatment (0, 8, 16, 24). Statistical values are included for each time point, with significant p-values below 0.05 marked for higher dose groups.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 09)

A line graph comparing the least squares mean changes in clinical outcomes over 24 weeks of treatment for Rivastigmine Transdermal System 13.3 mg/24 hr and 4.6 mg/24 hr. The x-axis represents weeks of treatment (0, 8, 16, 24), and the y-axis indicates least squares mean change with standard error bars, ranging from clinical improvement to clinical decline. Statistical significance values are noted at weeks 16 and 24.*

FDA Label Image

Figure A (71882343 E933 4efe A4e7 894ec2558222 10)

Illustration showing the components of the Rivastigmine Transdermal System from Zydus Pharmaceuticals USA Inc. It includes the pouch packaging, the transdermal patch labeled 'Rivastigmine Transdermal System,' protective liners on both sides of the patch, the adhesive layer containing medicine, and the outside backing layer.*

FDA Label Image

Figure B (71882343 E933 4efe A4e7 894ec2558222 11)

Illustration showing recommended application sites for Rivastigmine transdermal patches. Areas indicated include the left or right upper arm (side and back), left or right side of the chest (front and back), and left or right lower back, each marked with a hatched square to denote patch placement.*

FDA Label Image

Figure C (71882343 E933 4efe A4e7 894ec2558222 12)

Illustration showing a hand holding a sealed package labeled Rivastigmine Transdermal System. A pair of scissors is cutting along a dotted line on the package, indicating how to open it. The package states it is for transdermal use and contains one system, with Rx only and partial manufacturer branding visible.*

FDA Label Image

Figure D (71882343 E933 4efe A4e7 894ec2558222 13)

An instructional diagram showing a person peeling apart the protective backing of a round transdermal patch, demonstrating how to open the packaging before applying the patch to the skin.*

FDA Label Image

Figure E (71882343 E933 4efe A4e7 894ec2558222 14)

An instructional illustration showing a person holding a transdermal patch. The diagram labels the 'Protective Liners' being peeled away from the sticky surface of the transdermal system, demonstrating how to prepare the patch for application.*

FDA Label Image

Figure F (71882343 E933 4efe A4e7 894ec2558222 15)

Illustration showing the application of a Rivastigmine extended-release transdermal patch to the upper back of a person. One hand holds the patch while the other smooths it onto the skin, demonstrating proper placement for the medication delivery.*

FDA Label Image

Figure G (71882343 E933 4efe A4e7 894ec2558222 16)

Illustration showing the proper placement of a transdermal patch on the upper back just beside the spine. A hand is depicted applying the patch, indicating correct application technique.*

FDA Label Image

Figure H (71882343 E933 4efe A4e7 894ec2558222 17)

An instructional illustration showing the application of a transdermal patch on the upper chest area. The image depicts one hand placing the patch on the skin while the other hand holds it steady, demonstrating how to apply the patch by pressing it onto the skin with a circular motion.*

FDA Label Image

Figure I (71882343 E933 4efe A4e7 894ec2558222 18)

Instructional illustration showing how to fold used Rivastigmine transdermal system patches with sticky sides together, slide the folded patch into an empty pouch, and place the pouch in the trash, emphasizing disposal away from children and pets.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 19)

Label for Rivastigmine Transdermal System 4.6 mg/24 hours, a prescription transdermal patch. The label indicates the product is for transdermal use only and contains 30 systems. It is manufactured by Zydus Pharmaceuticals USA Inc. The NDC code 70710-1196-7 is shown.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 20)

Rivastigmine Transdermal System 9.5 mg/24 hours patch label. The packaging indicates the product is for transdermal use only and contains 30 systems. It is a prescription drug labeled by Zydus Pharmaceuticals USA Inc. The label includes the NDC 70710-1197-7 and features the Zydus Pharmaceuticals logo.*

FDA Label Image

Rivastigmine Transdermal System (71882343 E933 4efe A4e7 894ec2558222 21)

Rivastigmine Transdermal System patch, extended release, delivering 13.3 mg per 24 hours. The packaging specifies transdermal use only and contains 30 systems. Labeler is Zydus Pharmaceuticals USA Inc. The label includes the NDC 70710-1198-7 and is marked Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.